Abstract
The emergence of the covid-19 disease pandemic caused by the 2019 novel coronavirus has required a re-evaluation of treatment practices for clinicians caring for patients with chronic lymphocytic leukemia (cll). The American Society for Hematology (ash) has provided a series of recommendations for the treatment of patients with cll during the pandemic, covering a range of topics, including testing for covid-19, cll treatment initiation and selection, use of immunoglobulin therapy, in-person monitoring, and treatment of patients with cll and covid-19. We summarize the ash recommendations and discuss their applicability as guidelines for the treatment of cll during the covid-19 pandemic in Canada.
Keywords:
Coronavirus; chronic lymphocytic leukemia; covid-19.
2020 Multimed Inc.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adenine / analogs & derivatives
-
Ambulatory Care / methods
-
Antineoplastic Agents / therapeutic use*
-
Appointments and Schedules
-
Betacoronavirus
-
COVID-19
-
Canada / epidemiology
-
Coronavirus Infections / complications
-
Coronavirus Infections / diagnosis
-
Coronavirus Infections / epidemiology*
-
Coronavirus Infections / therapy
-
Disease Management
-
Hospitalization
-
Humans
-
Immunoglobulins, Intravenous / therapeutic use
-
Immunologic Factors / therapeutic use*
-
Leukemia, Lymphocytic, Chronic, B-Cell / complications
-
Leukemia, Lymphocytic, Chronic, B-Cell / therapy*
-
Pandemics
-
Piperidines
-
Pneumonia, Viral / complications
-
Pneumonia, Viral / diagnosis
-
Pneumonia, Viral / epidemiology*
-
Pneumonia, Viral / therapy
-
Practice Guidelines as Topic
-
Pyrazoles / therapeutic use
-
Pyrimidines / therapeutic use
-
SARS-CoV-2
Substances
-
Antineoplastic Agents
-
Immunoglobulins, Intravenous
-
Immunologic Factors
-
Piperidines
-
Pyrazoles
-
Pyrimidines
-
ibrutinib
-
Adenine